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ABSTRACT
Ovarian cancer is one of the highest causes of death among female population in Malaysia. A retrospective cohort 
study among 127 ovarian cancer patients registered in one of the teaching hospital in Malaysia was conducted from 1st 
January 2002 until 31st December 2011. The objective of this study was to determine the median survival time, five year 
survival probability and prognostic factors of ovarian cancer patients. Only ovarian cancer patients were selected with 
strict inclusion and exclusion criteria. Data was analyzed using Kaplan-Meier Survival analysis and Cox proportional 
hazard regression analysis. The results showed that the overall five-year survival probability of ovarian cancer was 
35.2% (95%CI: 26.3, 44.3) with 38 month (95%CI: 25.7, 50.1) median survival time. After adjustment for potential 
cofounder, significant prognostic factors of ovarian cancer were observed in FIGO stage (HR: 2.53; 1.44, 4.45), loss of 
appetite (HR: 1.95; 1.23, 3.11) and presence of pleural effusion (HR: 1.98; 1.19, 3.30). Overall, the survival probabilities 
of ovarian cancer were low and further actions must be taken to improve the survival among advanced cancer patients
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ABSTRAK
Kanser ovari merupakan salah satu penyebab utama yang membawa kepada kematian dalam kalangan populasi wanita 
di Malaysia. Satu kajian kohort retrospektif dalam kalangan 127 orang pesakit kanser ovari yang berdaftar di salah 
sebuah hospital pelatih perubatan di Malaysia telah dijalankan dari 1 Januari 2002 sehingga 31 Disember 2011. Objektif 
kajian ini adalah untuk mengkaji mengenai tempoh median kelangsungan hidup, keberangkalian kelangsungan hidup 
untuk lima tahun dan faktor prognostik bagi pesakit kanser ovari. Hanya pesakit kanser ovari dipilih berdasarkan kriteria 
rangkuman dan penyisihan yang ketat. Data kajian ini dianalisis menggunakan analisis ‘Kaplan-Meier Survival’ dan 
analisis  regresi  bahaya berkadaran Cox. Hasil kajian ini menunjukkan bahawa keseluruhan lima tahun kebarangkalian 
kelangsungan hidup bagi pesakit kanser ovari adalah 35.2% (95%SK: 26.3, 44.3) dengan median kelangsungan hidup 
selama 38 bulan (95%SK: 25.7, 50.1). Selepas penyesuaian untuk potensi pengasas bersama, faktor prognostik bererti 
kanser ovari telah diperhatikan pada tahap FIGO (NB: 2.53; 1.44, 4.45), kurang selera makan (HR: 1.95; 1.23, 3.11) dan 
kehadiran pleural efusi (NB: 1.98; 1.19, 3.30). Secara keseluruhannya, kebarangkalian kelangsungan hidup bagi pesakit 
kanser ovari di Malaysia adalah rendah dan tindakan selanjutnya mesti dilakukan untuk meningkatkan kelangsungan 
hidup dalam kalangan pesakit kanser kronik.
Kata kunci: Faktor prognostik; kanser ovari; kebarangkalian kelangsungan hidup; median kelangsungan hidup
INTRODUCTION
Ovarian cancer is a commonly diagnosed and a deadly 
gynaecological malignancy worldwide. This type of cancer 
is ranked as the top ten diagnosed cancer and deadliest 
cancer among women in the world. It is estimated that a total 
of 238,700 new cases of ovarian cancer have been reported 
worldwide in 2012. Based on this 2012 report, 99,800 of 
new cases were reported in more developed regions, 139,000 
of the cases being reported in less developed regions and 
111,900 of the cases have been reported in Asia (Ferlay et 
al. 2015). 
 In 2007, ovarian cancer is the fourth most common 
cancer among female in Malaysia with a total of 656 cases 
been diagnosed. It ranked as the third most common cancer 
among female in Kelantan with a total of 40 cases were 
diagnosed during the same year (Zainal Ariffin & Nor Saleha 
2011) (Table 1). 
 The five year survival rate varies greatly across the 
country. The patients in developed country reported higher 
five year survival rate compared with those in developing 
country. For example, a developed country such as Singapore 
reported higher five year survival rate (62%) compared to 
a developing country such as Thailand with 47% five year 
survival rate. This situation showed that high advancement 
in medical services and availability of diagnostic facilities 
may lead to a better survival rate (Wong et al. 2012). 
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 Ovarian cancer is well known as a ‘silent killer’ 
disease. The disease is usually asymptomatic during early 
stage causes more than two third of the patients only been 
diagnosed during advanced stage where the chances of cure 
is poorer compared to less advanced stage cancer (Goff et 
al. 2004; Ozols 2005). One study by Bankhead et al. (2005) 
found that most patients were facing difficulty to identify 
the symptoms of ovarian cancer; They had mistakenly 
assuming the symptoms as a normal changes in the body 
due to the effect of child bearing, menopause or ageing 
(Bankhead et al. 2005). 
 The prognostic factors of ovarian cancer were varies 
across different study. Some report have found out that 
younger women with early stage ovarian cancer and better 
differentiated tumours had higher survival probability 
compared to older women. However, other study had found 
out that age was not the independent prognostic factor after 
adjusting for other variables such as stage and grade of 
disease (Chan et al. 2008).
 Since there is inconsistent prognostic factor of ovarian 
cancer across different study, this study was conducted to 
identify the real prognostic factors of ovarian cancer after 
adjusting for potential cofounders. The aim of this study was 
to determine the median survival time, five year survival 
probability and the prognostic factor of ovarian cancer. 
This study was conducted in Malaysian population, with 
different ethnic group where the cultural, geographical, 
belief and lifestyle here are different with other country in 
the world. Thus, the results from this study were expected 
to give some positive impact to reduce mortality rate among 
patients with ovarian cancer in Malaysia.
METHODS
STUDY DESIGN AND PARTICIPANTS
This study was a retrospective cohort study using patient 
record review. All ovarian cancer patients registered in one 
of the teaching hospital in Malaysia (Hospital Universiti 
Sains Malaysia) from 1st January 2002 until 31st December 
2011 were recruited in the study. There was an additional 
one year follow-up period after the recruitment phase to 
determine patients’ survival status especially for those who 
were recruited at the end of study. 
 Sample size was calculated using PS Power software. 
The reference to calculate the sample size was referred 
from a study by Tingulstad et al. (2003) using the size of 
residual disease variable. The calculated sample size in 
this study was 141 patients. However, only 127 patients 
were selected after considering the inclusion and exclusion 
criteria (Figure 1).  Since the sample size obtained was less 
than the calculated sample size, no sampling method was 
applied. An ethical approval was obtained from the Human 
Research Ethics Committee Universiti Sains Malaysia and 
the permission to review patients’ folder was approved by 
Deputy Chairman, Human Research Ethics Committee 
from Hospital Universiti Sains Malaysia (reference number 
: USM/JEPeM/276.3.(8)).
STATISTICAL ANALYSIS
Data was analysed using Descriptive Analysis to 
summarize, organize and simplify the data. The frequency, 
percentage, mean and standard deviation for demographic 
background of the patients were summarized using this 
analysis.
TABLE 1. Incidence of ovarian cancer
Region Year Rank of cancer 
among female
Number of 
cases
Age standardized rate 
per 100,000 women 
(Incidence)
World 
More developed regions
Less developed regions
Asia
Malaysia
Kelantan
2012
2012
2012
2012
2007
2007
8
6
9
9
4
3
238,719
99,752
138,967
111,887
656
40
6.1
9.2
5.0
5.0
5.9
6.6
(Ferlay et al. 2014; Zainal Ariffin & Nor Saleha 2011) 
FIGURE 1. Kaplan-Meier survival estimate among ovarian 
cancer patients in Hospital USM with 49 censored 
observation (n=127)
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 The Kaplan-Meier Survival Analysis was used 
to determine the overall 5-years survival probability 
and median survival time of ovarian cancer. The Cox 
Proportional Hazard Regression analysis was used to 
identify the prognostic factor of ovarian cancer (Table 2). 
RESULTS
SOCIO-DEMOGRAPHIC OF THE SUBJECTS
There were 127 patients’ medical records included in 
this study after considering the inclusion and exclusion 
criteria. The main endpoint of this study was death among 
78 (61.4%) patients while other 49 (38.6%) patients 
were censored observations. Censored observations were 
patients who are still survive at the end of maximum follow 
up period, died due to other causes and lost to follow-
up. The overall mean age was 47.8 (SD 15.5) years with 
majority of the patients were Malay (89.0%) compared to 
non-Malay (11.0%). Majority of the patients were married 
(59.8%), some were divorced/widow (16.5%) and single 
(23.6%). 
MEDIAN SURVIVAL TIME AND FIVE YEAR 
SURVIVAL PROBABILITY
The cumulative survival probability curve for 127 patients 
with ovarian cancer registered in Hospital University 
Sains Malaysia (HUSM) from January 2002 until 
December 2011 is shown by Kaplan-Meier curve with 
median survival time was 38 month (95%CI: 25.7,50.1) 
and five year survival prob ability was 35.2% (95%CI: 
26.3,44.3).
PROGNOSTIC FACTORS OF OVARIAN CANCER
The variables that were selected in this study were 
categorized into three main categories that are patient-
related characteristics, disease-related characteristics 
and treatment-related characteristics. From Simple Cox 
Proportional Hazard Regression Analysis, four variables 
from patient-related characteristics, seventeen variables 
from disease-related characteristics and three variables 
form treatment-related characteristics had significant value 
less than 0.25 and were considered as potential prognostic 
factors (Table 3).  These variables were then analysed with 
Multiple Cox Proportional Hazard Regression Analysis to 
confirm the prognostic factor of the study.
 Three significant prognostic factors for ovarian 
cancer found were stage at diagnosis, loss of appetite and 
presence of pleural effusion. The findings are as follow: 
Ovarian cancer patients who were in advanced stage during 
diagnosis are 2.53 times higher risk (HR: 2.53; 95% CI: 
1.44, 4.45) to die from ovarian cancer compared with those 
in early stage cancer during diagnosis; Ovarian cancer 
patients who had symptom loss of appetite before the 
diagnosis of ovarian cancer are 95% higher risk (HR: 1.95; 
1.23, 3.11) to die from ovarian cancer compared with those 
who did not experience loss of appetite; and Ovarian cancer 
patients who had pleural effusion were 98% higher risk 
(HR: 1.98; 1.19, 3.30) to die from ovarian cancer compared 
with those who did not had pleural effusion (Table 4).  
 The assumption checking was done, showed that 
there was no possible interaction and correlation present 
between significant variables. The powerful assumption 
checking was done by global test showed a non-significant 
result (p=0.325). This showed that the proportional hazard 
assumption for survival analysis was met. The result from 
global test showed that hazard is proportional over time 
and hazard ratio is constant over time. 
DISCUSSION
The result from current study showed that the overall five 
year survival probability was 35.2% with median survival 
time 38 months. This findings were almost similar with 
previous study that was conducted among 480 incident 
cases of ovarian cancer in Norway with five-year survival 
probability of 39% and another study among 3482 women 
with epithelial ovarian cancer treated in general hospital 
in Netherland also showed five-year survival probability 
of 38% (Tingulstad et al. 2003; Vernooij et al. 2008). 
Nicholson et al. (1998) concluded that in general the 
overall five-year survival probability of ovarian cancer 
was around 30%.
 In this study, cancer stage showed a significant value 
with the hazard ratio of 2.53. As compared with other 
studies, this study showed a lower hazard ratio. A study 
from Wong et al. (2012) in Hong Kong found that the 
hazard ratio increase to 9.7 for stage four ovarian cancer 
TABLE 2. Five year survival rate of ovarian cancer patients in some population based series
Population Period of diagnosis % 5-year survival 
rate(95% CI)
Hong Kong
Singapore
South Korea
Turkey
Thailand
India
1997-2006
1993-1997
1993-2001
1995-1997
1990-2000
1990-2000
53.1 (60.8,65.5)
62
59(52-64)
60
47(45-58)
25(19-29)
(Wong et al. 2012)
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TABLE 3. Prognostic factors of ovarian cancer in Hospital USM by simple Cox regression
Covariate ba Crude HRb
(95%CI)
 Wald 
 Statistic
p-value
Age 0.02 1.02(1.00,1.03)  5.02 0.022
Marital status
  Married
 Divorce/widow
  Single
 
0
0.35
 -3.1
 
1
1.41(0.80,2.50)
 0.74(0.41,1.32)
 
 
 1.42
  1.07
 
 
0.234
 0.301
Number of gravida 0.09 1.09(1.02,1.17)  6.18 0.013
Occupation
  Student
  Employed
  Housewife/unemployed
 
0
1.28
1.47
 
1
3.61(1.44,9.00)
4.33(1.57,11.96)
 
 
 7.54
 8.00
 
 
0.006
0.005
Stage at diagnosis
  Early stage
  Advanced stage 
 
0
1.2
 
1
3.32(1.95,5.66)
 
 
 19.42
 
 
<0.001
Laterality
  Left 
  Right
  Bilateral
  Unknown
 
0
-0.58
0.12
-0.49
 
1
5.60(0.32,0.98)
1.13(0.65,1.98)
0.61(0.14,2.61)
 
 
 4.11
 0.19
 0.44
 
 
0.043
0.666
0.508
Consistency
  Cystic
  Firm 
  Hard 
  Unknown 
 
0
-0.00
0.47
-0.20
 
1
0.99(0.53,1.88)
1.60(0.84,3.07)
0.82(0.39,2.74)
 
 
 0
 2.01
 0.26
 
 
0.992
0.157
0.610
Ultrasound Findings
  Cystic
  Solid
  Mixed
  Unknown
 
 0
0.35
0.95
1.07
 
 1
1.42(0.61,3.28)
2.58(1.29,5.15)
2.92(1.15,7.45)
 
  
 0.67
 7.25
 5.05
 
  
0.415
0.007
0.025
CA125
  Normal
  Raised
 
0
0.93
 
1
2.51(1.35,4.66)
 
 
 8.42
 
 
0.004
Lost of appetite
  No
  Yes
 
0
0.90
 
1
2.45(1.56,3.84)
 
 
 15.14
 
 
<0.001
Lost of weight
  No
  Yes 
 
0
0.60
 
1
1.83(1.17,2.85)
 
 
 7.00
 
 
0.008
Lethargy
  No
  Yes
 
0
0.99
 
1
2.30(1.33,5.48)
 
 
 7.53
 
 
0.006
Ascites
  No
  Yes
 
0
0.66
 
1
1.94(1.22,3.09)
 
 
 7.87
 
 
0.005
Pleural effusion
  No
  Yes 
 
0
1.16
 
1
3.19(1.98,5.16)
 
 
 22.55
 
 
<0.001
Abdominal mass
  No
  Yes
 
0
-0.53
 
1
0.59(0.38,0.92)
 
 
 5.32
 
 
0.021
Uterus
  No
  Yes
 
0
0.50
 
1
1.65(0.89,3.05)
 
 
 2.52
 
 
0.113
(contiune)
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Rectum
  No
  Yes
 
0
0.57
 
1
1.76(1.01,3.06)
 
 
 4.00
 
 
0.045
Omentum
  No
  Yes
 
0
0.76
 
1
2.14(1.37,3.36)
 
 
 11.06
 
 
0.001
Colon
  No
  Yes
 
0
0.62
 
1
1.87(1.16,2.99)
 
 
 6.71
 
 
0.010
Lung
  No
  Yes
 
0
0.95
 
1
2.59(1.18,5.68)
 
 
 5.63
 
 
0.018
Liver
  No
  Yes
 
0
0.86
 
1
2.37(1.38,4.07)
 
 
 9.68
 
 
0.002
Surgery type
  Salphingoophorectomy
  Salphingoophorectomy + omentectomy 
 TAHBSO
  Debulking surgery
  No surgery
 
0
-0.40
 0.57
1.44
1.75
 
1
0.67(0.14,3.31)
 1.78(0.54,5.84)
4.21(1.29,13.70)
5.76(1.15,28.85)
 
 
 0.82
  0.61
 0.60
 0.82
 
 
0.622
 0.345
0.017
0.033
Treatment received
  Surgery only
  Surgery + chemotherapy
  Surgery + chemotherapy + radiotherapy
  No treatment
 
0
0.88
1.18
 1.67
 
1
2.41(1.10,5.28)
3.24(1.03,10.23)
 5.32(1.37,20.74)
 
 
 4.87
 4.01
  5.81
 
 
0.027
0.045
 0.016
Refuse further treatment
  No
  Yes
 
0
0.41
 
1
1.51(0.79,2.87)
 
 
 1.58
 
 
0.209
aRegression coefficient
bCrude hazard ratio
Covariate ba Crude HRb
(95%CI)
 Wald 
 Statistic
p-value
Continued (TABLE 3)
TABLE 4. Final model of Cox proportional hazard regression for prognostic factor 
among ovarian cancer patients in Hospital USM (n=127)
Characteristics n(%) Crude HRa
(95%CI)
Adjusted HRb
(95% CI)
Wald
 Statisticc (df)
p-valued
Stage at diagnosis
  Early stage
  Advanced stage
47(37.0)
80(63.0)
0
3.32(1.95,5.66)
1
2.53(1.44,4.45) 10.39(1) 0.001
Lost of appetite
  No
  Yes
79(62.2)
48(37.8)
0
2.45(1.56,3.83)
1
1.95(1.23,3.11) 7.99(1) 0.005
Pleural effusion
  No
  Yes
97(76.4)
30(23.6)
0
3.19(1.98,5.16)
1
1.98(1.19,3.30) 7.00(1) 0.008
Forward stepwise was applied. Two-way interaction and multicollinearity problem were checked and not detected. Proportional hazard assumption were fulfilled 
(hazard function plot, log-minus-log plot and Schoenfeld residual were checked) Regression diagnostic of Cox-Snell residual, Martingale residuals, deviance residuals 
and influential analysis were assessed. Remedial measure were perform to identify any influential outliers based on 20% changes of regression coefficients.
a Hazard ratio of Simple Cox Hazard Regression
b Hazard Ratio of Multiple Cox Proportional Hazard Regression
c Wald statistic of Multiple Cox Proportional Hazard Regression
d P-value of Wald statistic in Multiple Cox Proportional Hazard Regression
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as compared to stage one ovarian cancer. The other 
study from O’Malley et al. (2003) in Nothern California 
and Tingulstad et al. (2003) in Norway also obtained 
higher hazard ratio of 11.8 for stage four ovarian cancers 
compared to stage one cancer (Table 5). A possible 
explanation for a lower hazard ratio in this study compared 
to other significant studies might happen when the patients 
from early stage during diagnosis developed to the advance 
stage throughout the treatment process. This situation 
will affect the survival probability and lead to the slight 
difference in hazard ratio between early and advanced 
stage cancer.
 The loss of appetite was found to be a significant 
prognostic factor of ovarian cancer. It was found that 
patients that developed this symptom had almost double 
risk to death compared to the patients who did not presence 
with this symptom. This finding was supported by a study 
from Quinten et al. (2009) using 10108 cancer patients 
in Europe that discovered that loss of appetite was the 
significant prognostic factor of survival with the hazard 
ratio of 1.05 (95%CI:1.03,1.06). 
 This current study identified that patients who had 
pleural effusion were 3.19 times higher risk to die from 
ovarian cancer compared with other patients who did not 
have pleural effusion. This finding seem to be consistent 
with other research which found out that patients who 
experienced pleural metastases were 50% more likely to 
die compared to other patients who experienced lymph 
node or other site metastases (Bonnefoi et al. 1999). 
Another retrospective study from Zamboni et al. (2015) 
from 2000 to 2011 towards 165 malignant pleural effusion 
in Brazil found that the ovary tumour is the significant 
prognostic factor among patients with malignant pleural 
effusions with the median survival time of 21 months.
 There are a few strength and limitations in this 
study. The usage of survival analysis is the best choice in 
analysing time to event data where the analysis account 
for censored data, and manage to handle data with subjects 
entering the study at different time. The survival analysis 
also can compare survival between groups and able to 
assess relationship between covariates and survival time.
 However, this study did not fulfil the required number 
of sample size (n=144). After considering the inclusion and 
exclusion criteria, the researcher only manage to obtain 
the total number of 127 subjects. However, the number of 
sample size is still acceptable since the insufficient sample 
size is less than 30% with the post hoc power of the study 
is 78.7%.
 In this study, some of the potential prognostic factors 
that have been reported previously in other study such 
as chemotherapy regime, laboratory findings, weight, 
duration of treatment and age at menarche were not 
considered because the data about these variables were 
vague, incomplete and unavailable in most of the patients’ 
record. Thus, to avoid these missing values from altered 
the findings of the study, the variables were excluded from 
the analysis.
CONCLUSION 
Overall, the survival of ovarian cancer was worrying 
with the low percentage. In this study, three significant 
prognostic factor were found to be significant in this study 
with the average hazard ratio almost double compared to 
low risk group. Thus, the prospective cohort study needs 
to be done to discover more effective and accurate test 
for early detection of ovarian cancer. Therefore, people 
are able to come at earlier stage before the symptoms of 
ovarian cancer such as loss of appetite and pleural effusion 
arises. This will give a better survival outcome to ovarian 
cancer patients and reduce mortality rate.
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